MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

HealthDay 15 November at 11.05 PM

Olfactory, Gustatory Dysfunction Decline in Years Following COVID-19


WEDNESDAY, Nov. 15, 2023 (HealthDay News) -- The prevalence of olfactory dysfunction (OD) and gustatory dysfunction (GD) declines in the three years after COVID-19 infection, according to a research letter published online Nov. 9 in JAMA Otolaryngology-Head & Neck Surgery.

Paolo Boscolo-Rizzo, M.D., from the University of Trieste in Italy, and colleagues estimated the three-year prevalence of measured OD and GD associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. One-hundred individuals who tested positive for SARS-CoV-2 were matched with 100 controls recruited from hospital staff who tested negative for SARS-CoV-2. Eighty-eight cases completed all follow-up assessments.

The researchers found that during the acute phase of COVID-19 and at one-, two-, and three-year follow-up, the prevalence of self-reported smell or taste dysfunction was 64.8, 31.8, 20.5, and 15.9 percent, respectively, among cases. The prevalence of OD decreased during follow-up, with frequency of 40.9, 27.3, and 13.6 percent of one-, two-, and three-year evaluations, respectively. Cases were more likely to have OD than controls at two years after infection (27.3 versus 10.2 percent); however, at three years after COVID-19, no significant excess of OD was identified (13.6 and 10.2 percent, respectively). At one-, two-, and three-year evaluation, the prevalence of GD was 26.1, 13.6, and 11.4 percent, respectively; at two and three years after COVID-19, there were no differences in GD observed between cases and controls.

"Patients with post-COVID-19 condition exhibiting chemosensory alterations should be reassured that a recovery of olfaction appears to continue over three years after initial infection," the authors write.

One author disclosed ties to the biopharmaceutical, medical device, and nutrition industries.

Abstract/Full Text (subscription or payment may be required)


Recent Comments


  • avatar